Trials / Completed
CompletedNCT00384423
Short Term Effects of PRX-03140 in Patients With Mild Alzheimer's Disease Being Treated With Aricept
A Randomized, Double-Blind, Placebo-Controlled, Phase IIa Study to Assess the Short-Term Effects of PRX-03140 Alone and in Combination With Donepezil in Subjects With Mild Alzheimer's Disease.
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 80 (estimated)
- Sponsor
- Epix Pharmaceuticals, Inc. · Industry
- Sex
- All
- Age
- 60 Years
- Healthy volunteers
- Not accepted
Summary
This is a study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of PRX-03140 administered orally once daily for 14 days in subjects with mild Alzheimer's Disease who are using a stable, well-tolerated 10 mg dose of Aricept (donepezil) but continue to experience worsening AD symptoms.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | PRX-03140 |
Timeline
- Start date
- 2006-10-01
- Primary completion
- 2007-10-01
- First posted
- 2006-10-06
- Last updated
- 2008-01-30
Locations
17 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00384423. Inclusion in this directory is not an endorsement.